Julie VanOrsdel Daves - 13 Sep 2022 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Role: SVP Clinical Development Oper.
Signature: /s/ Amy Culbert, attorney-in-fact
Issuer symbol: DMAC
Transactions as of: 13 Sep 2022
Net transactions value: $0
Form type: 4
Filing time: 15 Sep 2022, 16:41:28 UTC
Next filing: 02 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	DMAC	Voting Common Shares, no par value per share						0	13 Sep 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DMAC	Stock Option (right to buy)	Award	$0	+140,000		$0.000000	140,000	13 Sep 2022	Common Shares	140,000	$1.47	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option vests with respect to 35,000 common shares on September 13, 2023 and with respect to the remaining 75% of the common shares in 36 nearly equal monthly installments commencing one month after the one-year anniversary of the grant date.